In toto, this report suggests that inhibition of NFκB expression and activity by YC-1 may provide therapeutic benefits in retinal diseases associated with enhanced VEGF and NFκB, such as ischemia-independent retinal microvasculopathies [15], [27], [31], [32], [33], [34], [35], [36]. Here, VEGFA is linked to ischemia.